Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network

S. Rattotti, V.V. Ferretti, C. Rusconi, A. Rossi, S. Fogazzi, L. Baldini, P. Pioltelli, M. Balzarotti, L. Farina, A.J.M. Ferreri, D. Laszlo, V. Speziale, M. Varettoni, R. Sciarra, L. Morello, A. Tedeschi, M. Frigeni, I. Defrancesco, C. Zerbi, E. Flospergher & 4 others M.E. Nizzoli, E. Morra, L. Arcaini, on behalf of the “Rete Ematologica Lombarda“ (REL - Hematology Clinical Network of Lombardy - Lymphoma Workgroup)

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)160-167
JournalHematological Oncology
Volume37
Issue number2
DOIs
Publication statusPublished - 2019

Keywords

  • antiviral therapy
  • chronic hepatitis C virus infection
  • cohort study
  • non-Hodgkin lymphomas
  • interferon
  • adult
  • aged
  • chronic hepatitis C
  • clinical trial
  • disease free survival
  • epidemiology
  • female
  • follow up
  • Hepacivirus
  • human
  • Italy
  • male
  • middle aged
  • mortality
  • multicenter study
  • nonhodgkin lymphoma
  • prospective study
  • survival rate
  • very elderly
  • Adult
  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Hepatitis C, Chronic
  • Humans
  • Interferons
  • Lymphoma, Non-Hodgkin
  • Male
  • Middle Aged
  • Prospective Studies
  • Survival Rate

Cite this

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. / Rattotti, S.; Ferretti, V.V.; Rusconi, C.; Rossi, A.; Fogazzi, S.; Baldini, L.; Pioltelli, P.; Balzarotti, M.; Farina, L.; Ferreri, A.J.M.; Laszlo, D.; Speziale, V.; Varettoni, M.; Sciarra, R.; Morello, L.; Tedeschi, A.; Frigeni, M.; Defrancesco, I.; Zerbi, C.; Flospergher, E.; Nizzoli, M.E.; Morra, E.; Arcaini, L.; Workgroup), on behalf of the “Rete Ematologica Lombarda“ (REL - Hematology Clinical Network of Lombardy - Lymphoma.

In: Hematological Oncology, Vol. 37, No. 2, 2019, p. 160-167.

Research output: Contribution to journalArticle

Rattotti, S. ; Ferretti, V.V. ; Rusconi, C. ; Rossi, A. ; Fogazzi, S. ; Baldini, L. ; Pioltelli, P. ; Balzarotti, M. ; Farina, L. ; Ferreri, A.J.M. ; Laszlo, D. ; Speziale, V. ; Varettoni, M. ; Sciarra, R. ; Morello, L. ; Tedeschi, A. ; Frigeni, M. ; Defrancesco, I. ; Zerbi, C. ; Flospergher, E. ; Nizzoli, M.E. ; Morra, E. ; Arcaini, L. ; Workgroup), on behalf of the “Rete Ematologica Lombarda“ (REL - Hematology Clinical Network of Lombardy - Lymphoma. / Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. In: Hematological Oncology. 2019 ; Vol. 37, No. 2. pp. 160-167.
@article{0edbc1781a384e6a90237b4001675fbf,
title = "Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network",
keywords = "antiviral therapy, chronic hepatitis C virus infection, cohort study, non-Hodgkin lymphomas, interferon, adult, aged, chronic hepatitis C, clinical trial, disease free survival, epidemiology, female, follow up, Hepacivirus, human, Italy, male, middle aged, mortality, multicenter study, nonhodgkin lymphoma, prospective study, survival rate, very elderly, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Follow-Up Studies, Hepatitis C, Chronic, Humans, Interferons, Lymphoma, Non-Hodgkin, Male, Middle Aged, Prospective Studies, Survival Rate",
author = "S. Rattotti and V.V. Ferretti and C. Rusconi and A. Rossi and S. Fogazzi and L. Baldini and P. Pioltelli and M. Balzarotti and L. Farina and A.J.M. Ferreri and D. Laszlo and V. Speziale and M. Varettoni and R. Sciarra and L. Morello and A. Tedeschi and M. Frigeni and I. Defrancesco and C. Zerbi and E. Flospergher and M.E. Nizzoli and E. Morra and L. Arcaini and Workgroup), {on behalf of the “Rete Ematologica Lombarda“ (REL - Hematology Clinical Network of Lombardy - Lymphoma}",
note = "Export Date: 26 June 2019 CODEN: HAOND Correspondence Address: Rattotti, S.; Division of Hematology, Fondazione IRCCS Policlinico San MatteoItaly; email: sararattotti@gmail.com",
year = "2019",
doi = "10.1002/hon.2575",
language = "English",
volume = "37",
pages = "160--167",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "2",

}

TY - JOUR

T1 - Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network

AU - Rattotti, S.

AU - Ferretti, V.V.

AU - Rusconi, C.

AU - Rossi, A.

AU - Fogazzi, S.

AU - Baldini, L.

AU - Pioltelli, P.

AU - Balzarotti, M.

AU - Farina, L.

AU - Ferreri, A.J.M.

AU - Laszlo, D.

AU - Speziale, V.

AU - Varettoni, M.

AU - Sciarra, R.

AU - Morello, L.

AU - Tedeschi, A.

AU - Frigeni, M.

AU - Defrancesco, I.

AU - Zerbi, C.

AU - Flospergher, E.

AU - Nizzoli, M.E.

AU - Morra, E.

AU - Arcaini, L.

AU - Workgroup), on behalf of the “Rete Ematologica Lombarda“ (REL - Hematology Clinical Network of Lombardy - Lymphoma

N1 - Export Date: 26 June 2019 CODEN: HAOND Correspondence Address: Rattotti, S.; Division of Hematology, Fondazione IRCCS Policlinico San MatteoItaly; email: sararattotti@gmail.com

PY - 2019

Y1 - 2019

KW - antiviral therapy

KW - chronic hepatitis C virus infection

KW - cohort study

KW - non-Hodgkin lymphomas

KW - interferon

KW - adult

KW - aged

KW - chronic hepatitis C

KW - clinical trial

KW - disease free survival

KW - epidemiology

KW - female

KW - follow up

KW - Hepacivirus

KW - human

KW - Italy

KW - male

KW - middle aged

KW - mortality

KW - multicenter study

KW - nonhodgkin lymphoma

KW - prospective study

KW - survival rate

KW - very elderly

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferons

KW - Lymphoma, Non-Hodgkin

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Survival Rate

U2 - 10.1002/hon.2575

DO - 10.1002/hon.2575

M3 - Article

VL - 37

SP - 160

EP - 167

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 2

ER -